Back to List View Graph View

Trastuzumab

Trastuzumab, marketed under the brand name Herceptin, is a monoclonal antibody that specifically targets human epidermal growth factor receptor 2 (HER2).

Where the papers sit

15 papers from the last 6 months study trastuzumab directly · updated from PubMed 16 Nov 2026

Those 15 are all about one subject.

  • HER2-Targeted Cancer Therapy

    HER2-targeted therapy is broadening beyond conventional trastuzumab toward drug-loaded nanoparticles, site-specific conjugates, radionuclide treatment and combination regimens. Resistance remains a central problem, with NEK2-linked m6A regulation and ferroptosis-related changes emerging alongside efforts to treat brain metastases. Molecular profiling and delivery engineering aim to improve tumour selectivity and overcome CNS barriers. Economic effects of biosimilars, breast-milk transfer and payload release remain important clinical and translational questions.

    15 papers

PARADIGM SHIFT

Radiation-carrying trastuzumab can overcome limitations of antibody-mediated HER2 inhibition, including in brain metastases

The [177Lu]Lu-DOTA-trastuzumab study in trastuzumab-resistant HER2-positive breast-cancer brain metastases and the [47Sc]Sc-NOTA-trastuzumab study in primary and metastatic HER2-positive breast-cancer models indicate that trastuzumab need not depend on signaling blockade alone to remain effective. The first found that radiolabeled trastuzumab caused DNA double-strand-break-mediated killing despite preserved HER2 expression and trastuzumab resistance, with complete remission in some established brain metastases; the second developed a radiolabeled trastuzumab that localized to HER2-positive tumors and was evaluated for activity in breast tumors and brain-metastasis models. Together, these findings replace the assumption that resistance to trastuzumab-mediated inhibition or brain-specific delivery barriers necessarily preclude trastuzumab-based treatment: trastuzumab can instead function as a carrier for cytotoxic radiation. 42734882Sep 42480146Jul

Papers

The 15 papers from the last 6 months that study trastuzumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

HER2-Targeted Cancer Therapy (15)
  1. Trastuzumab-conjugated Docetaxel-loaded Nanostructured Lipid Carriers for Gastric Cancer. AAPS PharmSciTech · 12 Nov 2026 PMID 43021037
  2. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  3. NEK2 promotes trastuzumab resistance in gastric cancer through WTAP/YTHDF1-dependent m6A regulation of FN1. Molecular biology reports · 16 Oct 2026 PMID 42886303
  4. Computational framework-guided engineering of microbial transglutaminase enables site-specific conjugation of Trastuzumab. Bioorganic chemistry · 29 Sept 2026 PMID 42809913
  5. 177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer. Molecular biomedicine · 14 Sept 2026 PMID 42734882
  6. Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer chemotherapy and pharmacology · 2 Sept 2026 PMID 42684430
  7. Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
  8. Focused Ultrasound-Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Aug 2026 PMID 42658183
  9. HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy. BMJ case reports · 24 Aug 2026 PMID 42637511
  10. FcBP-HFQ lipid-mediated trastuzumab modification of mRNA-loaded lipid nanoparticles enhances delivery to HER2-expressing cancer cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 18 Aug 2026 PMID 42612711
  11. A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer. Cancer medicine · 27 Jul 2026 PMID 42504645
  12. Development and characterization of [47Sc]Sc-NOTA-trastuzumab for targeted radiotherapy in primary and metastatic HER2 + breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480146
  13. LC-MS/MS Quantification and Solvent-Exposure Modeling Reveal a Mismatch Between Linker Exposure and Payload Release in Wild-Type Trastuzumab-VC-PABC-MMAE in Rat Plasma. Biomedical chromatography : BMC · 20 Jul 2026 PMID 42476813
  14. Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
  15. Transfer of trastuzumab and pertuzumab into human breast milk: a case report. Cancer chemotherapy and pharmacology · 20 May 2026 PMID 42159752

By study type

Clinical trials (1)
  1. A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer. Cancer medicine · 27 Jul 2026 PMID 42504645
Observational studies and case reports (3)
  1. Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
  2. HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy. BMJ case reports · 24 Aug 2026 PMID 42637511
  3. Transfer of trastuzumab and pertuzumab into human breast milk: a case report. Cancer chemotherapy and pharmacology · 20 May 2026 PMID 42159752
Human data, design not indexed (3)
  1. Uncovering the full economic impact of biosimilars: a "would have spent" counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016-2025. Journal of medical economics · 28 Oct 2026 PMID 42948929
  2. Computational framework-guided engineering of microbial transglutaminase enables site-specific conjugation of Trastuzumab. Bioorganic chemistry · 29 Sept 2026 PMID 42809913
  3. Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
Preclinical: animal, cell and lab studies (7)
  1. Trastuzumab-conjugated Docetaxel-loaded Nanostructured Lipid Carriers for Gastric Cancer. AAPS PharmSciTech · 12 Nov 2026 PMID 43021037
  2. NEK2 promotes trastuzumab resistance in gastric cancer through WTAP/YTHDF1-dependent m6A regulation of FN1. Molecular biology reports · 16 Oct 2026 PMID 42886303
  3. 177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer. Molecular biomedicine · 14 Sept 2026 PMID 42734882
  4. Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer chemotherapy and pharmacology · 2 Sept 2026 PMID 42684430
  5. Focused Ultrasound-Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Aug 2026 PMID 42658183
  6. Development and characterization of [47Sc]Sc-NOTA-trastuzumab for targeted radiotherapy in primary and metastatic HER2 + breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480146
  7. LC-MS/MS Quantification and Solvent-Exposure Modeling Reveal a Mismatch Between Linker Exposure and Payload Release in Wild-Type Trastuzumab-VC-PABC-MMAE in Rat Plasma. Biomedical chromatography : BMC · 20 Jul 2026 PMID 42476813
Unclassified: not yet indexed with MeSH (1)
  1. FcBP-HFQ lipid-mediated trastuzumab modification of mRNA-loaded lipid nanoparticles enhances delivery to HER2-expressing cancer cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 18 Aug 2026 PMID 42612711